Skip to main content
. 2020 Feb 26;20:92. doi: 10.1186/s12872-020-01384-6

Table 3.

Effect of Baseline and Longitudinal Pulse Rates on Outcomes

Pulse rate (bpm) Baseline
Crude
HR or RRa (95% CI)
Baseline Multivariablec
HR or RRa (95% CI)
Longitudinal
Crude
HR or RRb (95% CI)
Longitudinal Multivariablec
HR or RRb (95% CI)
All-Cause Mortality (HR) 47–59 0.91 (0.84–0.98) § 0.85 (0.76–0.94) § 0.92 (0.86–0.98) § 0.84 (0.78–0.90) ||
60–63 0.95 (0.88–1.02) 0.90 (0.81–1.00) 0.93 (0.87–0.99) § 0.86 (0.80–0.94) §
64–67 0.99 (0.92–1.07) 0.92 (0.83–1.02) 0.92 (0.86–0.98) § 0.88 (0.81–0.95) §
68–71 0.99 (0.92–1.07) 1.01 (0.92–1.12) 0.96 (0.90–1.02) 0.90 (0.83–0.97) §
72–75
76–79 1.10 (1.02–1.18) § 1.11 (1.01–1.22) § 1.07 (0.99–1.14) 1.09 (1.00–1.18)
80–83 1.07 (1.00–1.16) 1.14 (1.04–1.27) § 1.10 (1.02–1.18) § 1.11 (1.02–1.21) §
84–88 1.06 (0.99–1.15) 1.15 (1.04–1.27) § 1.19 (1.11–1.28) || 1.22 (1.12–1.33) ||
89–96 1.13 (1.05–1.22) § 1.25 (1.14–1.38) || 1.41 (1.32–1.52) || 1.55 (1.42–1.68) ||
97–117 1.21 (1.12–1.30) || 1.43 (1.30–1.58) || 1.84 (1.71–1.97) || 2.03 (1.86–2.21) ||
All-Cause Hospitalizations (RR) 47–59 0.79 (0.70–0.90) § 0.84 (0.73–0.97) § 0.95 (0.87–1.02) 1.00 (0.90–1.10)
60–63 0.91 (0.80–1.03) 0.98 (0.85–1.13) 0.91 (0.84–0.99) § 0.93 (0.85–1.03)
64–67 0.92 (0.81–1.04) 0.96 (0.84–1.10) 0.90 (0.83–0.98) § 0.89 (0.81–0.98) §
68–71 0.94 (0.84–1.06) 1.02 (0.90–1.16) 0.96 (0.89–1.04) 1.02 (0.92–1.13)
72–75
76–79 1.12 (0.99–1.26) 1.16 (1.02–1.31) § 1.01 (0.93–1.09) 1.06 (0.95–1.18)
80–83 1.21 (1.08–1.36) || 1.19 (1.04–1.35) § 1.17 (1.07–1.28) § 1.22 (1.09–1.37) §
84–88 1.24 (1.10–1.39) || 1.18 (1.04–1.34) § 1.18 (1.09–1.29) || 1.19 (1.06–1.34) §
89–96 1.28 (1.14–1.44) || 1.11 (0.98–1.26) 1.44 (1.32–1.56) || 1.43 (1.29–1.59) ||
97–117 1.48 (1.32–1.65) || 1.30 (1.14–1.47) || 2.06 (1.89–2.25) || 1.85 (1.66–2.07) ||
Heart Failure Hospitalizations (RR) 47–59 0.68 (0.49–0.93) § 0.68 (0.48–0.97) § 0.79 (0.57–1.08) 0.88 (0.66–1.17)
60–63 0.77 (0.56–1.06) 0.87 (0.62–1.23) 0.84 (0.59–1.19) 0.97 (0.70–1.36)
64–67 0.72 (0.52–0.99) § 0.73 (0.52–1.03) 0.65 (0.47–0.89) § 0.66 (0.50–0.86) §
68–71 0.96 (0.73–1.28) 1.02 (0.76–1.38) 0.86 (0.59–1.26) 0.98 (0.72–1.33)
72–75
76–79 1.18 (0.89–1.56) 1.23 (0.91–1.64) 0.92 (0.65–1.30) 1.19 (0.81–1.76)
80–83 1.27 (0.97–1.68) 1.20 (0.89–1.62) 1.05 (0.75–1.45) 1.20 (0.90–1.61)
84–88 1.38 (1.06–1.80) § 1.23 (0.92–1.64) 1.06 (0.76–1.46) 1.24 (0.92–1.68)
89–96 1.33 (1.01–1.74) § 1.09 (0.81–1.46) 1.38 (1.00–1.92) 1.61 (1.18–2.21) §
97–117 1.85 (1.43–2.39) || 1.64 (1.24–2.17) § 2.11 (1.53–2.92) || 2.29 (1.65–3.17) ||

HR Hazard Ratio, RR Rate Ratio, bpm beats per minute

aPoisson regression model

bNegative Binomial regression model

cMultivariable models were adjusted for age, gender, race, BMI, eGFR, serum potassium, serum sodium, use of beta blockade, ARBs, ACEIs, nitrates, statins, aldosterone antagonists, calcium channel blockers, loop diuretics, and history of coronary artery disease, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, dementia, diabetes, stroke/TIA, cardiovascular disease and anemia. The baseline multivariate model was additionally adjusted for baseline LVEF and the longitudinal multivariate was adjusted for development of atrial fibrillation or atrial flutter

§p < .05 ||p < .0001